Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Caribou Biosciences (CRBU) EBITDA: 2019-2024

Historic EBITDA for Caribou Biosciences (CRBU) over the last 6 years, with Dec 2024 value amounting to -$148.9 million.

  • Caribou Biosciences' EBITDA rose 18.11% to -$27.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$157.8 million, marking a year-over-year decrease of 7.84%. This contributed to the annual value of -$148.9 million for FY2024, which is 48.11% down from last year.
  • As of FY2024, Caribou Biosciences' EBITDA stood at -$148.9 million, which was down 48.11% from -$100.5 million recorded in FY2023.
  • Caribou Biosciences' 5-year EBITDA high stood at -$34.3 million for FY2020, and its period low was -$148.9 million during FY2024.
  • Its 3-year average for EBITDA is -$116.7 million, with a median of -$100.8 million in 2022.
  • As far as peak fluctuations go, Caribou Biosciences' EBITDA slumped by 95.46% in 2021, and later rose by 0.28% in 2023.
  • Yearly analysis of 5 years shows Caribou Biosciences' EBITDA stood at -$34.3 million in 2020, then slumped by 95.46% to -$67.1 million in 2021, then plummeted by 50.32% to -$100.8 million in 2022, then increased by 0.28% to -$100.5 million in 2023, then slumped by 48.11% to -$148.9 million in 2024.